Humacyte Reports Symvess Reduces Costly Complications in Extremity Arterial Injury Repair

Reuters
01/08
Humacyte Reports Symvess Reduces Costly Complications in Extremity Arterial Injury Repair

Humacyte Inc. announced the results of a five-year retrospective analysis examining hospital charges, payer costs, and healthcare resource utilization in patients with extremity arterial injury. The study found that the average hospital charge for initial extremity arterial injury repair was $316,600 per patient. Preventable complications, such as amputation and conduit infection, increased hospital charges by approximately $493,000 and $590,000 per patient, respectively. The analysis also indicated that Humacyte’s Symvess, an acellular tissue engineered vessel, demonstrated low rates of infection and high rates of limb salvage. All data were collected prior to FDA approval of Symvess and reflect healthcare economics before its commercialization. The results have already been announced by the company.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Humacyte Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9621911) on January 08, 2026, and is solely responsible for the information contained therein.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10